Drugs / Bone Marrow Aspirate
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02319720 | Jul 2008 → Mar 2013 | ulcer disease | Dr. E.Badiavas | Terminated | No outcome recorded Stop: Business |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05517434 | Jan 2025 → Jun 2026 overdue | osteoarthritis, knee | University Health Network, Toronto | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06238934 | Mar 2024 → Mar 2025 overdue | osteoarthritis, knee | National Institute of Traumatology and Orthopaedics | Not yet recruiting | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06893302 | Feb 2026 → Apr 2029 expected | osteoarthritis, knee | Hospital for Special Surgery, New York | Recruiting | No outcome recorded |
| — | NCT07242729 | Feb 2025 → Feb 2027 expected | plantar fasciitis | Federal University of São Paulo | Recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT05507099 Comparator | Aug 2022 → Aug 2028 expected | osteoarthritis | Grigory Karmy | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03580148 Comparator | Oct 2015 → Jul 2020 | osteoarthritis | Women's College Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bone Marrow Aspirate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07242729 ↗ |
| Known as | BMA | “Bone Marrow Aspirate (BMA): Minimally manipulated autologous cellular preparation” NCT05517434 ↗1“Biological: Bone Marrow Aspirate (BMA)” NCT06893302 ↗ |
| Modality | Cell therapy | “Autologous Cell Therapy.” NCT05507099 ↗ |
| Route | Other | “Fresh bone marrow aspirate administered to the wound at the time the bone marrow is taken.” NCT02319720 ↗ |